{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "ff2c69dd0ef537f94fc37b586af1dcbd",
    "title": "Jefferies",
    "source_uri": "2025-08-29/C-Suite Back to School Fireside Chat SeriesC-Suite Back to School Fireside Chat Series_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:39:26.736444",
      "extracted_at": "2025-10-27T00:39:26.736451"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 19,
        "successful_pages": 19,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 1,
          "reduction_ratio": 0.1693030987817865
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "2bf56cd7ac12e7c1",
      "text": "C- Suite \"Back to School\" inside Chat Series",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b645a5d1ddfd98a0",
      "text": "Now in its 4th year, with our C- Suite Back to School\" Fireside Chat Series we are catching up with c.40 companies across the wider Jefferies EU Healthcare coverage universe. Resuming on Monday, September 1, we'll gain insights & new perspectives & have meaningful conversations ahead of results & other important events. We hope you can join us for timely & insightful discussions.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2a527bd2cc676a96",
      "text": "You'll have an opportunity to hear from a further \\(39x\\) companies (\\* New), incl. NOVN, COPN, GMAB, SECARE, IPN, DMP, SAN, QGEN, DOCM, SFZN, ALM, SN/LN, FRE, HIK, HLUNB, SOBI, ZEAL, RDC, VIMIAN, SPI, DIA, REC, BAYN, ROVI, PETS, ORNBV, FME, GSK, RICHT, ALKB, CAMX, DEMANT, EKTAB, CVSG, \\*GALD, OXB, ROG, SDZ. More to come! Click HERE to register for any of the confirmed companies in the series or individual links below.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a76e70bc51689876",
      "text": "1. \\*NEXT WEEK\\* Novartis AG (NOVN SW): Mon 1 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "15d3029e25f77b39",
      "text": "2. \\*NEXT WEEK\\* COSMO Pharmaceuticals NV (COPN SW) Tue 2 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "02c68019d4eb7da8",
      "text": "3. \\*NEXT WEEK\\* Genmab A/S (GMAB) Tue 2 Sep - 15:30 BST / 16:30 CEST / 10:30 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3e9da6ee19670fdd",
      "text": "4. \\*NEXT WEEK\\* SwedenCare AB (SECARE SS) Wed 3 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4c425343cc607382",
      "text": "5. \\*NEXT WEEK\\* Ipsen (IPN FP) Wed 3 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "82700b93179a015e",
      "text": "6. \\*NEXT WEEK\\* Dermapharm Holding SE (DMP GR) Thu 4 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9de21c1262bea134",
      "text": "7. \\*NEXT WEEK\\* Sanofi (SAN FP) Thu 4 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1f669e4ea553e5e3",
      "text": "8. \\*NEXT WEEK\\* Qiagert (QGEN) Thu 4 Sep - 15:30 BST / 16:30 CEST / 10:30 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c5deb49f33cf09d1",
      "text": "9. DocMorris App (DOCM SW) Tue 9 Sep - 16:00 BST / 17:00 CEST / 11:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b50056ed209100a8",
      "text": "10. Siegfried (SFZN) Wed 10 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8b5688188bb0649e",
      "text": "11. Altairall (ALM SM) Wed 10 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5590b57d81418d4a",
      "text": "12. Smith & Nephew (SN/LN) Fri 12 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d0cf4118db27af07",
      "text": "13. Fresenius SE & Co. KGaA (FRE GR) Mon 15 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "14c8c90bc8553719",
      "text": "14. Hikma Pharmaceuticals PLC (HIK LN) Mon 15 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "60b37dc9eb5c548c",
      "text": "15. Lundbeck (HLUNB DC) Mon 15 Sep - 16:00 BST / 17:00 CEST / 11:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f53d51baa8291161",
      "text": "16. Swedish Orphan Biovitrum AB (SOBI SS) Tue 16 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "615e25d622f4c7ff",
      "text": "17. Zealand Pharma A/S (ZEAL DC) Tue 16 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "32af038fa286af66",
      "text": "18. Redcare Pharmacy (RDC GR) Wed 17 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "798f80e50ad14f68",
      "text": "19. Vimian Group (VIMIAN) Thurs 18 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a25600b6b9ad692d",
      "text": "20. Spire Healthcare Group PLC (SPI LN) Tue 23 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c8f037be5c8f8d63",
      "text": "21. Diagnostyka Group (DIAG PW) Wed 24 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7c48f0b445add66c",
      "text": "22. Recordati Industria Chimica E Farmaceutica S.P.A (REC IM) Wed 24 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "824f00cc7857cd87",
      "text": "23. Bayer AG (BAYN GR) Thu 25 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9d0902e2ea5e06d8",
      "text": "24. Laboratorios Farmaceuticos Rovi (ROVI SM) Thu 25 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ec5663e4757749c4",
      "text": "25. Pets at Home (PETS LN) Thu 25 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8f0d0fb9b1e3f8b8",
      "text": "26. Orion Oyj (ORNBV FH) Mon 29 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5d90f717b7ad53cc",
      "text": "27. Fresenius Medical Care (FME GR) Tue 30 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "66eab93f9fd90970",
      "text": "28. GSK (GSK LN) Tue 30 Sep - 15:30 BST / 16:30 CEST / 10:30 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f8bc4a10e37413f7",
      "text": "29. Gedeon Richter (RICHT HB) Wed 1 Oct - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c445c4cbf5b7dca5",
      "text": "30. ALK-Abello (ALK BC) Thu 2 Oct - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2c032cb530c17b4d",
      "text": "The list continues on the following pages",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1bc88fabf7a087f8",
      "text": "31. Demant (DEMANT DC) Fri 3 Oct - 12:00 BST 3:00 CEST / 7:00 EDT REGISTER32. Camurus AB (CAMX SS) Thu 9 Oct - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER33. Elekta (EKTA BSS) Mon 20 Oct - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER34. CVS Group (CVSG LN) Tue 28 Oct - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER35. \\*NEW\\* Galderma Group (GALD SW) - Wed 29 Oct 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER36. Oxford Biomedica plc (OXB LN) Tue 4 Nov - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER37. Roche (ROG SW) Wed 5 Nov - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER38. Sandoz Group AG (SDZ SW) Tue 11 Nov - 10:15 BST / 11:15 CEST / 5:15 EDT - REGISTER",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e56cd69117533cb5",
      "text": "Novartis AG (NOVN SW): Mon 1 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b872a80a4710000f",
      "text": "Patrick Horber, M.D., International President / Isbella Zinck, IR Manager",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6db3cf08bf17bbf4",
      "text": "We will be joined by Novartis' International President Patrick Horber to discuss progress in ex- US drug launches and strategy. In particular, we will explore recent progress made with expanding patient access to Leqvio for high cholesterol, as well as views on potential Kisqali growth following the recent expansion of the label to include patients with early breast cancer. In addition, we will consider expectations for Cosentyx and how growth dynamics may differ from the US market. Finally, we will explore management's views on drug pricing in International markets, including comparisons vs US and how differences could be mitigated in the face of ongoing scrutiny from US politicians.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1253cb9fb5a4debd",
      "text": "COSMO Pharmaceuticals NV (COPN SW) Tue 2 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3a073191277e1353",
      "text": "We will be joined by Cosmo's CFO to further explore the company's refined strategy presented at the recent Investor Day, including key drivers behind management's new 2030 financial ambitions. Initial focus will be placed on hair loss therapy Breezula ahead of anticipated Phase III headlines in 3Q25E, with intention to explore the assumptions behind the commercial opportunity. We will also discuss recent market research that has driven optimism for the opportunity, plus management's potential strategy which aims to realise the full value of the asset. We will also explore evolution of the broader pipeline, including regional expansion of acne cream Winlevi, plus the financial implications of expanding the Al- powered GI Genius platform.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9e1de81730eb97dd",
      "text": "Genmab A/S (GMAB) Tue 2 Sep - 15:30 BST / 16:30 CEST / 10:30 EDT - REGISTER",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "82ceff889b4b5233",
      "text": "Anthony Pagano, Executive Vice President & CFO",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "46e352ad252a3d23",
      "text": "Join us for a fireside chat with Genmab's CFO to discuss the company's near- term outlook, including the development strategies in place to navigate the expected decline in Darzalex royalties later in the decade. We will touch on internal R&D strategy and the required investments, as well as consideration of management's experience of the current M&A environment, ultimately to assess management's interest in externally- sourced innovation. Finally, we intend to explore the need for antibody innovation beyond oncology, for example in Immunology and Inflammation.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d372d60d98fa09a7",
      "text": "SwedenCare AB (SECARE SS) Wed 3 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "27ee8847633f85d1",
      "text": "Hakan Lagerberg, CEO",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3e8ce1dc5e8a41bd",
      "text": "We will explore Swedencare's strategic pivot from an M&A- driven expansion phase to a renewed focus on operational execution and margin recovery, following a period of soft quarters impacted by timing effects and transitional headwinds. Key discussion points will include the company's entry into Big Box retail, the in- house transition of Amazon account handling, the ramp- up of high- margin Pharma manufacturing, and its disciplined bolt- on M&A strategy. We will also assess the outlook for achieving medium- term margin expansion targets and the implications of a more selective capital allocation approach. The session will provide insight into Swedencare's readiness to scale profitably and strengthen its leadership in the global pet health market.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fe95306413089735",
      "text": "Ipsen (IPN FP) Wed 3 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d2d2d13e667b9d15",
      "text": "Aymeric Le Chatelier, EVP, Group CFO",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5aee5312fd682651",
      "text": "Join us to discuss Ipsen's new growth story, underpinned by key assets including Iqirvo, Dysport and Bylvay, which are also expected to help offset loss of exclusivities for Onivyde (2029E) and Cabometryx (2029E). We will touch on the erosion dynamics for Somatuline, which has experienced a series of sales beats over the last few quarters, with a generic- like decline expected for the",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "334ec91bcbf7274d",
      "text": "remainder of the year. We will also explore business development, which continues to be a top priority, with the aim of targeting assets with peak sales of €300- 800m, as well as its pipeline with the anticipated readout of long- acting neurotoxin for aesthetic purposes during 2H25E.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c15d0cd87809a952",
      "text": "Dermapharm Holding SE (DMP GR) Thu 4 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT REGISTER",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "5fa74b9bc8c8f1ce",
      "text": "Christof Drehholz, CFO & CCO / Britta Hamberger, Head of Investor Relations & Corporate Communications / Ann- Cathrin Drewes, Investor Relations & Corporate Communications",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "22317a399d9c0160",
      "text": "We will look at the company's differentiated positioning in the attractive branded pharmaceuticals space, growth prospects of the core portfolio as well as expansion potential from internationalisation efforts. We will furthermore touch on progress made with Arkopharma and respective synergies to unfold across the platform, in particular for market access and logistics.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "238af4a5042cfe30",
      "text": "Sanofi (SAN FP) Thu 4 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8d7ee95cba0c4301",
      "text": "Management's decision to hike R&D spend to support Sanofi's growing immunology & inflammation portfolio is likely justified given the growing number of assets progressing through to late- stage development, in our view. During our fireside with Sanofi's CFO, we will discuss expectations for how these R&D investments are expected to evolve, plus discuss updated thoughts on key margin drivers. We will also explore the current US political environment, including investments into the US, exposure to potential drug pricing pressure, and strategies to mitigate exposure to potential US import tariffs. Finally, following the company's recent large M&A deal, we will also look to discuss management's expectations for further business development.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "4336fc31c096c411",
      "text": "Qiagen (QGEN) Thu 4 Sep - 15:30 BST / 16:30 CEST / 10:30 EDT - REGISTER",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9efa31c08e2cd331",
      "text": "Thierry Bernard, CEO / John Gilardi, Vice President Head of Corporate Communications / Domenica Martorana, Associate Director Global Investor Relations",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "606dd0672bfb5670",
      "text": "One of the top- performing Tools companies YTD, with material upside left in multiple (e.g., trading at 13x '26E EBITDA vs. \\(>16x\\) Tools average) in spite of above average growth profile ( \\(\\sim +5\\%\\) organic in '25 vs. \\(\\sim +2\\%\\) Tools avg) amidst broader sector weakness. Multipronged R&D engine (e.g., five pillar strategy) fueling secular growth story led with new product launches, idiosyncratic growth drivers (e.g., digital PCR), and market leadership positions (e.g., QuantIFERON) with opportunity for algorithm to inflect higher in '26 and beyond on A&G / biotech recovery. Prudent use of shareholder capital with recently announced inaugural dividend ( \\(0.25 / sh\\) ) and \\(\\)500M\\(of buybacks in flight, while management focused non- dilutive M&A and portfolio right- sizing (e.g., NeuMoDx divestment). Industry- leading EBIT margins ( \\(>30\\%\\) ) with opportunities for further expansion ( \\(+100bps\\) by '28) and \\(+\\) DD EPS growth potential (vs. \\(+8\\%\\) consensus).",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7eb497328645ba1b",
      "text": "DocMorris AG (DOCM SW) Tue 9 Sep - 16:00 BST / 17:00 CEST / 11:00 EDT - REGISTER",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "0b27167cabc1395b",
      "text": "Walter Hess, CEO / Moritz Stahlhut, IR Manager",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "750589b28f827545",
      "text": "We will discuss the key topics in DOCM's investment case such as market growth, competitive landscape, margin expansion and innovations such as Telemedicine and the introduction of the electronic prescription in Germany. We will also touch on DOCM's longer- term strategy and the path to achieving management's mid- term guidance by navigating through various uncertainties in a structural channel shift equity story.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9f5541d879923c95",
      "text": "Siegfried (SFZN) Wed 10 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "dd329082ded5ce6e",
      "text": "Following a softer 1H25 performance but a reaffirmation of full- year guidance, a check- in with management presents a valuable opportunity for investors to assess the progress of the required",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "59d4946f05dad6b9",
      "text": "2H25 ramp- up. Key topics from the 1H call- including the ramp- up of the Minden site, pricing dynamics, and the seasonality of the Drug Product market, remain critical, and further detail on these areas will be essential to evaluate momentum through the remainder of the year. Additionally, the company has emphasized that M&A is a strategic priority. Any insight into the characteristics of ideal acquisition targets would help clarify potential upside to consensus expectations.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5600c7210a36efee",
      "text": "Almirall (ALM SM) Wed 10 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1a017ab8bf54e3ed",
      "text": "Carlos Gallardo Pique, President & CEO / Jon U Garay, CFO & CSO",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9bce5bdf7f83552e",
      "text": "Almirall's YTD share price performance is a testament to the company's de- risked nature, despite sector headwinds. We will discuss the company's dermatology growth story, led by Ebglyss (lebrikizumab) for atopic dermatitis and Ilumetri for psoriasis. We will examine how the Ebglyss launch is progressing in Europe, as well as how physicians position the drug alongside incumbent Dupixent and newly launched Nemulvio. For Ilumetri, we will focus on drivers for continued growth and how Almirall plans to navigate increasing biosimilar use in Europe. We will also touch on other key dermatology brands, particularly Klisryi for actinic keratosis and Wynzora for psoriasis. Earlier this year, Almirall revealed its mid- term targets, thus we will explore the expected evolution of EBITDA margin expansion, as well as business development priorities.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a13c710f6381afb3",
      "text": "Smith & Nephew (SN/LN) Fri 12 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "164ee69df9b157e2",
      "text": "After a strong end to '24 and a solid start to '25, investors' confidence in improved sales consistency and margin goal for '25 (and beyond) has gotten a boost. Compounded by mild impact from tariffs/ macro/FX, activism and appealing valuation, SN has been perceived as a 'safe haven' with the shares up >10% YTD (one of the best perf in the sector). This will be a good opportunity to discuss with CEO how the company is now reaping the benefits from portfolio shifting toward faster growth segments and recent R&D efforts, which support higher, sustainable growth. We will also touch on the prospects for further margin improvement beyond '25 and some 'easy wins' left (share buyback, biz unit accountability, focus on ROIC).",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "b769f33a99f9bd4e",
      "text": "Fresenius SE & Co. KGaA (FRE GR) Mon 15 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "be2cfba8fcad10e4",
      "text": "Michael Sen, Chairman of the Management Board / Nick Stone, Head of IR",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "143531ede152e769",
      "text": "Capital allocation is the key debate around the name given the recent reduction in the FME stake. The debt paydown this enabled removed a significant obstacle to investor enthusiasm and potential for future paydowns and utilization of this new financial flexibility will be of key interest to investors. The biosimilars market and regional hospital market dynamics are areas investors should look for insight given the pivotal role these play for the outlook of the company. With ongoing transformation initiatives and a renewed focus on operational efficiency, we hope this presentation gives the company an opportunity to demonstrate its strategy to unlock shareholder value.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f1b835842f6ecb3d",
      "text": "Hikma Pharmaceuticals PLC (HIK LN) Mon 15 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "507555d92c1c3dc3",
      "text": "The CMD earlier this year confirmed the thesis behind our preceding upgrade, as the company announced a pivot to a more large scale, complex generics strategy, now renamed Rx. Catching up with the company will give investors an update on this strategy and any further details the company wants to emphasize. The injectables business remains a driver for the top and bottom line, so insight is always a welcome driver of sentiment while biosimilar pricing remains a key debate for investors for both HIK and the wider industry. The ramp and integration of the Xellia assets and the wider generics market remain key factors in investor sentiment, and so an update on these key dynamics will also be useful.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0ea2cffa140427e9",
      "text": "Charl van Zyl, President & CEO",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ec8b27e5b88df1a2",
      "text": "Join us to explore Lundbeck's key growth drivers, notably Rexulti and Vyepti, as well as plans to address patent expiries for Trintellix/Brintellix (2026) and Abilify Maintena (off- patent). Lundbeck's \\(\\) 2.6bn\\(acquisition of Longboard Pharmaceuticals for Phase III asset bexicaserin in 2024 was a significant milestone for the company, so we will also discuss the integration and the progress of the studies. Additionally, we will explore the potential of other pipeline candidates, such as anti - PACAP for migraine prevention and amelentug for multiple systems atrophy, alongside expectations for the remainder of the year and the mid- term period.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "27daf073cc126340",
      "text": "Guido Oelkers, CEO / Gerard Tobin, Head of Investor Relations",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1f29e59c16d19b22",
      "text": "We will discuss the US launch of haemophilia A drug Altuviio, for which Sobi receives royalties from Sanofi in the region, EU launch, as well as uptake vs factor and Hemlibra. Moreover, we will examine Beyfortus in RSV, particularly under the lens of seasonality given actual immunisation rates were lower than expected earlier in the year, and considering potential US launch of US Merck's clesrovimab for the 2025- 2026 season. We will also touch on NASP in chronic refractory gout and Aspaveli in C3G and IC- MPGN, with launch anticipated during 2026E, as well as Vonjo's uptake so far in myelofibrosis. We will close by discussing the outlook for the remainder of the year and business development.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7af89105eacfc62e",
      "text": "Following a \"best case\" amylin deal with Roche, we will explore Zealand CEO's updated thinking about the evolving obesity landscape, including how management is positioning its asset toolbox to provide differentiated treatments for patients. We will explore updated thoughts around the potential positioning of petrelintide (long acting amylin) ahead of key Phase IIB results in 1H26E, plus discuss recent data from the broader amylin landscape presented at ADA. We will also touch on survodutide GLP- 1/Glu as partner Boehringer's Phase III readout nears in 1H26E, plus how management hopes the drug to be positioned given potential benefits for liver disease MASH. Zealand also has a rare disease portfolio, for which we will examine the commercial opportunities, partnership strategies, and expected approval timelines.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "67e4c00c74339f0d",
      "text": "We will address in more detail the key topics in RDC's investment case such as market growth, competitive landscape, margin expansion and innovations such as Telemedicine and the introduction of the electronic prescription in Germany. We will also touch on RDC's longer- term strategy and the path to achieving management's mid- term guidance by navigating through various uncertainties in a structural channel shift equity story.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "86a04e38befd988d",
      "text": "We will unpack Vimian's strategic pivot in the wake of a challenging 2025 and the abrupt CEO exit in July, as interim CEO/CFO Carl- Johan Zetterberg Boudrie steers the group toward execution, integration, and margin repair. Discussion will centre on the normalization of US orthopedics, progress on dental integration (including iM3), and the Specialty Pharma ramp- up that underpinned early- year strength. We'll also examine the recent AllAccem acquisition, how a more selective bolt- on M&A and deleveraging framework is reshaping capital allocation, and what these moves",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "5d59fc7c9cc28483",
      "text": "signal for restoring EBITA margins and reigniting organic growth as Virminan seeks to reinforce its leadership in global animal health.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "9daeb9879040ea6d",
      "text": "Spire Healthcare Group PLC (SPI LN) Tue 23 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fba4b226297653ab",
      "text": "Justin Ash, CEOThis is an opportunity for investors to gain direct insight into the strategies and future plans of one of the UK's leading independent hospital groups. Key topics will include the company's approach to navigating the evolving healthcare landscape and how the respective divisions will be adapted. Strategies for driving margin- accretive, sustainable growth will be at the forefront of this discussion. Savings plans have been highlighted by the company in recent months, and any detail regarding the phasing or ABS impact of these will be insightful for observers.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a70a6d0531df8e35",
      "text": "Diagnostyka Group (DIAG PW) Wed 24 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "74c2fd44aa68a334",
      "text": "Pawel Chytla, CFO / Michal Blasinski, IR Directo",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6cc99bc02d9f549d",
      "text": "Since the IPO earlier this year, Poland's largest provider of medical diagnostic services has seen its share price appreciate \\(c.27\\%\\) . This is a key time to speak with management as the company prepares for its next stage of growth and details the levers behind this. Key topics to watch for are the margin expansion potential as well as the current M&A environment and how DIA can use this to drive the topline. Any insight on the wider Polish Macro environment would also be well received.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "45810fd61d1e504f",
      "text": "Recordati Industria Chimica E Farmaceutica S.P.A (REC IM) Wed 24 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ecfb2d3009dbfe1f",
      "text": "Robert Koremans, CEO / Luigi La Corte, Group CFO",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "df3145693f05cc93",
      "text": "We look forward to hosting Recordati's CEO and CFO to discuss the company's established Rare Diseases (RD) and Specialty & Primary Care (SPC) businesses, especially in light of the new midterm targets. On RD, we will focus on the uptake of Enjaymo following the acquisition from Sanofi in 2024, as well as Isturisa post- label expansion, and the US commercial potential of Qarziba, which is yet to obtain FDA approval. On SPC, we aim to discuss the recent acquisition of Vazke pa, plus the strategy to maintain or even continue to grow margins year- on- year, despite the largely genericised nature of the assets in the portfolio. Additionally, given its importance to Recordati, we seek incremental detail on future M&A.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "28791c6eee5a0cb4",
      "text": "Bayer AG (BAYN GR) Thu 25 Sep - 13:00 BST / 14:00 CEST / 8:00 EDT - REGISTER",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b0a1a7032bdbe011",
      "text": "Stefan Oelrich, Member of the Board of Management and Head of the Pharmaceuticals Division & Alexander Siedler, IR Officer",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "8c43a3fdadc4c419",
      "text": "We'll discuss how Bayer's new products, Nubeqa and Kerendia, are helping to offset value loss from Xarelto, while also reviewing the pipeline of future launch assets and the evolving performance of other key products like Eylea and Mirena. We plan to discuss operational changes and progress within the division from its Dynamic Shared Ownership restructuring strategy, and potential compensation for weaker margin mix of its evolving product portfolio.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "dc14416f9af11e1a",
      "text": "Laboratorios Farmaceuticos Rovi (ROVI SM) Thu 25 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bd93e3e0c64af26b",
      "text": "Javier Lopez- Belmonte Encina, CFO",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "057e27f00a19eb96",
      "text": "The company is entering a pivotal phase of its strategic evolution, having decided to retain the CDMO business versus a potential divestment. As such, new customer contracts to fill the recent capacity expansions are the key levers to driving the stock and removing the discount currently placed on it. This primary CDMO business is supported by a strong specialty pharmaceutical",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fff01c60e7f63695",
      "text": "division- anchored by long- acting injectable Okedi, the potential of which can also provide upside to current expectations. Management has also outlined a forward- looking capital allocation framework during its recent CMD, signaling a commitment to sustainable value creation.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "12f841e28a14530f",
      "text": "Pets at Home (PETS LN) Thu 25 Sep - 15:00 BST / 16:00 CEST / 10:00 EDT - REGISTER",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "db8c9a80fb8764fc",
      "text": "Lyssa McGowan, CEO / Andrew Porteous, IR Director",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8f5714ca92736a96",
      "text": "After a challenging FY24, which saw forecasts lowered as its Retail operation faced into a combination of cost headwinds, a promotional industry backdrop, and consumer cyclical pressures, Pets at Home is looking ahead with growing confidence. Key tech and infrastructure projects - that should drive growth and efficiencies - have been landed, FY25 forecasts have been rebased conservatively, trading comps are getting weaker, and the Vet business continues to go from strength to strength. We continue to view PETS as the dominant player in the UK pet care market, and expect the combination of self- help and a return to market growth in Retail, alongside further gains in the Vet Group, to drive meaningful profit progress in FY27 and beyond.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "2ec98a9ea6c903d5",
      "text": "Orion Oyj (ORNBV FH) Mon 29 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "c275da500ad32b50",
      "text": "Liisa Hurme, CEO / René Lindell, CFO / Tuukka Hirvonen, Head of IR",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "6420c78fb0727eeb",
      "text": "As one of the best- performing stocks within our healthcare coverage to- date, this is a timely opportunity to hear from the CEO, particularly on the underlying market demand for Bayer- partnered Nubeqa and quarterly sales momentum. We also aim to discuss opevesostat, partnered with US Merck, and currently in two Phase III studies for metastatic castration- resistant prostate cancer, with radiographic progression- free survival data potentially during 2026E. We plan to touch on potential headwinds to Nubeqa from Xtandi generics in 2028, the commercial potential of insomnia candidate ODM- 105, as well as business development strategy, particularly in the Generics & Consumer Health and Animal Health units.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "522df241b0c0c473",
      "text": "Fresenius Medical Care (FME GR) Tue 30 Sep - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "9f9b2f5064ccdc1b",
      "text": "Helen Giza, CEO & Chair of the Management Board / Alicia Cahill, Senior IR Director",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "6131d0c6d40fc27a",
      "text": "It is a timely opportunity to hear from the company in the wake of the recent CMD. The latest market dynamics and the path to a more normalised volume growth will be top of the list for investors as well as insight into the new savings plan. The topline growth potential of the company given the potential headwind of GLP- 1/SGLT2 drugs for the space. Wider market factors such as payer dynamics and the rollout of the next generation HDF machines will also be sentiment drivers into the midterm and hence a topic to look forward to.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "81ece70a470745ae",
      "text": "GSK (GSK LN) Tue 30 Sep - 15:30 BST / 16:30 CEST / 10:30 EDT - REGISTER",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8d65ec8a985aaa36",
      "text": "Luke Miels, Chief Commercial Officer",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "5a57b2333f758db5",
      "text": "The key focus of our fireside chat will be exploring the pipeline opportunities that underpin confidence in management's >£40bn 2031 sales aim. In particular, we will discuss the set up for campilixant for chronic cough ahead of expected Phase III readout in 2026, plus GSK's strategy in oncology given ongoing late- stage studies for Jemperli & Blenrep, as well as earlier- stage B7H3/ B7H4 antibody drug conjugates acquired from Hansoh. We will also explore rationale for recent acquisitions of IDRx and Boston Pharmaceuticals, plus the expected balance between leveraging internal and external sources of innovation going forward.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "55e038e892e16e4a",
      "text": "Gedeon Richter (RICHT HB) Wed 1 Oct - 14:00 BST / 15:00 CEST / 9:00 EDT - REGISTER",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e8ca5c58b4416a41",
      "text": "Following the 10 year business update earlier this year, RICHT will continue to highlight the business potential of the company ex- Vraylar, hence we believe this is a format where investors can gain a",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "92b1587cca00fd76",
      "text": "detailed insight into this expansion. Biosimilars is a new market the company aims to penetrate, and insight into the progress of this can also provide read- across to competitors as well as a status update on the current pricing environment. The expansion of share in WHC and the progress of the pipeline with ABBV are also key levers for investors to check in on.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "2892948ea2461ad9",
      "text": "ALK's impressive growth continues to be driven primarily by European tablet sales, with investor focus recently beginning to shift to near- term launches of allergy tablets for paeds and adrenaline nasal spray neffy. Discussion will initially focus on recent trends in allergy tablets across the European market, plus potential signals into the coming patient initiation season to help investors understand the potential for near- term volume growth. We will then explore ongoing launches of paediatric tablets & neffy, with the ultimate aim to assess management's confidence in achieving its mid- term sales and profits aims through to 2028.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b07e186cfc879822",
      "text": "Søren Nielsen, President & CEO / Peter Pudselykke, Head of Investor Relations",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "60277467e327192a",
      "text": "It is a timely opportunity to hear from the CEO on the next platform launch given its latest techno is \\(>12m\\) old and competitive pressure has likely peaked. We will also touch on latest data suggesting sequential improvement in the hearing aid market after a rough ride since 2H24 and prospects for the French market given the all- important, widely- assumed recovery. Besides, we will focus on the recent strategic deal for Kind to cement a leadership position in the German Retail market, tailwinds from US Managed Care (return on United's catalog to help from 2H25) and latest FX moves impacting profitability. Shares have regained \\(\\sim 20\\%\\) in the past 3M (by far the best performer across our coverage), now trading at a \\(10\\%\\) discount vs peer Sonova (in line with 10yr avg).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4cdd5ff8f960bde8",
      "text": "We will explore the latest dynamics of the buprenorphine market and Brixadi/Buvidal's uptake in its respective regions for opioid- use disorder. Additionally, we will discuss catalysts that should drive further upside, including potential approval of Oclaz/OCzyesa in acromegaly, progress on and expectations for CAM2029 in GEP- NET, with Phase III data expected YE25- 1Q26E, plus Phase III development of CAM2029 in polycystic liver disease. We will also touch on Camurus' recent deal with Eli Lilly, for up to \\(\\) 870m\\(, as well as the company's wholly- owned GLP - 1 asset which is in a Phase I study vs Wegovy.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8a35abc9554d2ab3",
      "text": "There will be lots to discuss with EKTAB's CFO including: 1/ The appointment of new CEO Jakob Just- Bomholt (former CEO of 3Shape), starting Sep '25 (link); 2/ Confidence about the company's FY25/26 targets (sales growth; no margin target) and mid- term guide (GM to return to pre- pandemic levels of \\(\\sim 40\\%\\) and EBIT margin \\(>14\\%\\) ); 3/ Ability to restore top- line momentum in light of order book trajectory and recent project cancellations to focus on high profitability orders; 4/ GM recovery is encouraging, but its sustainability remains uncertain. EKTAB shares have declined by \\(\\sim 30\\%\\) over the past year and are currently trading near historical lows, at \\(\\sim 13x\\) P/E CY25e. This valuation appears to reflect a combination of external pressures—including tariff and FX headwinds—as well as investor caution around the company's operational trajectory.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "fcc649650f6ab3a7",
      "text": "Richard Fairman, CEOThe vet clinics sector in the UK has enjoyed a strong performance YTD, despite the recent announcement of a delay in the CMA announcement. Investor enthusiasm is hence warranted as longer- term uncertainties have abated. Inflationary pressures and other headwinds are not removed, however, despite the sector's staple vs. discretionary characteristics, and so an opportunity to discuss these points and other market dynamics with management should be a useful event for investors. International prospects, notably in Australia where CVS has expanded more recently, will also be a sentiment driving topic.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "a718f327448450c2",
      "text": "\\\\*NEW\\\\*Galderma Group (GALD SW)- Wed 29 Oct 14:00 BST/15:00 CEST/9:00 EDT- REGISTER",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f01accc2988b74a6",
      "text": "Thomas Dittrich, CFOWe will be joined by Thomas Dittrich, CFO, and Emil Ivanov, IR, to discuss Galderma's strategy as a unique pure play dermatology company. We will discuss current trends in the injectable aesthetic market, including recent developments in market share and demand, plus approaches employed by management to continue category leadership. In addition, we will explore the ongoing launch of Nemluvio for atopic dermatitis and prurigo nodularis to gauge performance versus initial expectations to help inform expectations going forwards. Finally, we will also review Galderma's recent financial performance and forward- looking strategy to better understand how the outgoing CFO is positioning Galderma ready for the next chapter of growth.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "01b929d34e0bc353",
      "text": "Oxford Biomedica plc (OXB LN) Tue 4 Nov - 14:00 BST/15:00 CEST/9:00 EDT - REGISTER",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "552e4ddc4e2e1ccc",
      "text": "Frank Mathias, CEO / Lucinda Crabtree, CFO / Sebastien Ribault, CBO",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "37eceb9e2d66e551",
      "text": "Frank Mathias, CEO / Lucinda Crabtree, CFO / Sebastien Ribault, CBOThis event will be a good opportunity for investors to check in with OXb in the wake of our initiation and 1H25 results. Key topics for discussion will be the planned CMD in 2H25 as well as any market growth data OXb is able to provide. Growth of the overall market is a key overhang on the stock, with investor sentiment depressed by recent biotech funding data. We believe positive market data points are key to driving the name as the discount is removed. Key contract signings and incoming levels of RFPs will also be key metrics to track to determine OXb's place within the market, irrespective of the wider market growth.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "8db06c7a8cabb817",
      "text": "Roche (ROG SW) Wed 5 Nov - 14:00 BST/15:00 CEST/9:00 EDT - REGISTER",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "39fc0e1a10d855fa",
      "text": "Dr. Alan Hippe, CFO / Bruno Eschli, Head of IR",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "39c74f31fc7c84af",
      "text": "Dr. Alan Hippe, CFO / Bruno Eschli, Head of IRJoin us for a fireside chat with Roche's CFO where we will explore the company's strategy to achieve management's aims of launching 20 transformative medicines and doubling patient access to high- value diagnostics solutions by 2029. Whilst the on- market Pharma portfolio is expected to deliver growth until 2028, we will dig further into the Roche pipeline, with focus on assets that could deliver underappreciated upside 2026E+, for example assets within the cardiovascular & metabolism and neurology portfolios. In addition, we will discuss the current macro environment, including updated thoughts on US political risks to drug pricing, plus expectations for potential sector specific tariffs. Finally, we will also explore Roche's M&A aspirations and experience within the current BD environment.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "02e06c951ce56363",
      "text": "Sandoz Group AG (SDZ SW) Tue 11 Nov - 10:15 BST/11:15 CEST/5:15 EDT - REGISTER",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "6fa1e581abb4fe06",
      "text": "Remco Steenbergen, CFO / Tamara Hackl, Senior Director Investor Relations",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "58c35164b6289df6",
      "text": "In the wake of a launch- heavy 2024, FY25 was marketed as more transitional, but despite this SDZ has had key newsflow points with which investors should remain up to date. The renegotiation of the Cordavis agreement, delay of the Tyruko JCV assay and potential regulatory requirements for biosimilars are all material points for both SDZ and the wider industry. Updates on these points as well as any further commentary regarding the launches or the wider biosimilar pricing environment",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "6f56d038e88d84b8",
      "text": "(a key driver of sentiment) will be key for stakeholders. An initial look at FY26 drivers may also be an interesting detail.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "7ed8199738c16ce2",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/ sellside/Disclosures.action or call 212.284.2300.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "da28b97ba32777e3",
      "text": "Registration of non- US analysts: Adela Dashian is employed by Jefferies GmbH, a non- US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7d8faac44dd9af4c",
      "text": "Registration of non- US analysts: Benjamin Jackson is employed by Jefferies International Limited, a non- US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "3658e1a8a33b3ceb",
      "text": "Registration of non- US analysts: Christopher Richardson, ACA is employed by Jefferies International Limited, a non- US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "fbef60f4c4e47aef",
      "text": "Registration of non- US analysts: Shan Hama is employed by Jefferies International Limited, a non- US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7845fb14cbda02e3",
      "text": "Registration of non- US analysts: Fabian Piasta is employed by Jefferies GmbH, a non- US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst. As is the case with all Jefferies employees, the analyst(s) responsible for the coverage of the financial instruments discussed in this report receives compensation based in part on the overall performance of the firm, including investment banking income. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Aside from certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "261186741315ed9e",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "726566810c75362d",
      "text": "August 29, 2025 5:42 A.M. August 29, 2025 5:42 A.M.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "a705dcf0e840b9ab",
      "text": "Jefferies is acting as financial advisor to Blueprint Medicines Corporation for Sanofi's acquisition of Blueprint Medicines Corporation. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADRs of Hikma Pharmaceuticals plc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADR of Oxford BioMedica plc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ARDs of Pets at Home Group Plc. Jefferies Financial Group Inc., its affiliates or subsidiaries make a market in the securities or ADRs of Smith & Nephew.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e8acca6524f1f5c2",
      "text": "Within the past twelve months, Diagnostyka has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "3724cdeda14bbb0a",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Diagnostyka or one of its affiliates within the past twelve months.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "75dcd10ef395d5fd",
      "text": "Jefferies International Ltd, its affiliates or subsidiaries has, or had, within the past 12 months an agreement to provide investment services to Diagnostyka. Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Diagnostyka.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "ed03583897570914",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Oxford BioMedica plc within the next three months.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "53d5669a5b07c89e",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Oxford BioMedica plc.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "ec7809f48493a04a",
      "text": "Jefferies International Limited acts as a corporate broker for Oxford BioMedica plc. Jefferies International Ltd, its affiliates or subsidiaries has, or had, within the past 12 months an agreement to provide investment services to Oxford BioMedica plc.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "723b8abc25f14361",
      "text": "Within the past twelve months, Oxford BioMedica plc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "6f5cfb22f4395ef0",
      "text": "Within the past twelve months, Pets at Home Group Plc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "88190d1b060f057c",
      "text": "Jefferies International Limited acts as a corporate broker for Pets at Home Group Plc.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "f50afc7ac8636105",
      "text": "Jefferies International Ltd, its affiliates or subsidiaries has, or had, within the past 12 months an agreement to provide investment services to Pets at Home Group Plc.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "2fc5b7f06f1f124a",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Pets at Home Group Plc.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "73930998ae0d35a7",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Pets at Home Group Plc within the next three months.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "d5993177b81c8605",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co- manager in the underwriting or placement of securities for Qiagen or one of its affiliates.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "7eb2539071d77c26",
      "text": "Within the past twelve months, Qiagen has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking services are being or have been provided.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "07fae766fac7342c",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Qiagen within the next three months.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "864173663034d14e",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Qiagen.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "201472d0d964fd1d",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Qiagen or one of its affiliates within the past twelve months.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "3d43c54d605f9f9b",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/ sellside/Disclosures.action or call 212.284.2300.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "68c69c6ccc5ab6e9",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "2d5b7c1e5c5108e1",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e54998287f4bd3f0",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "93254f5d50628626",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "df48d8d32c80d2e8",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "10ea32cb2f2d697b",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e24e1ae3ccfec4e6",
      "text": "Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e939262600ef152e",
      "text": "Jefferies Franchise PicksJefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9848b7bb36ddc20e",
      "text": "ALK- Abello A/S (ALKB DC: DKK200.20, BUY)",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "3ffcbfcd2d0133dd",
      "text": "- Almirall (ALM SM: €11.40, BUY)- Bayer AG (BAYN GR: €27.93, HOLD)- CVS Group (CVSG LN: p1,270.00, HOLD)- Camurus AB (CAMX SS: SEK726.50, BUY)- Cosmo (COPN SW: CHF62.40, BUY)- Demant (DEMANT DC: DKK243.00, HOLD)- Dermapharm Holding SE (DMP GR: €33.00, HOLD)- Diagnostyka (DIA PW: PLN203.80, BUY)- DocMorris AG (DOCM SW: CHF6.61, BUY)- Elekta (EKTAB SS: SEK46.64, HOLD)- Fresenius Medical Care (FME GR: €43.10, UNDERPERFORM)- Fresenius SE (FRE GR: €46.36, BUY)- GSK Plc (GSK LN: p1,459.50, HOLD)- Galderma Group AG (GALD SW: CHF139.80, BUY)- Gedeon Richter Plc. (RICHT HB: HUF10,490, BUY)- Gemba A/S (GMAB DC: DKK1,612.50, HOLD)- Hikma Pharmaceuticals plc (HIK LN: p1,815.00, BUY)- Ipsen (IPN FP: €117.90, HOLD)- Laboratorios Farmaceuticos Rovi SA (ROVI SM: €58.35, BUY)- Lundbeck (HLUNB DC: DKK40.38, HOLD)- Novartis AG (NOVN SW: CHF101.54, HOLD)- Orion Oyj (ORNBV FH: €68.50, BUY)- Oxford BioMedica plc (OXB LN: €5.71, BUY)- Pets at Home Group Plc (PETS LN: p227.80, BUY)- Qiagen (QGEN: $46.14, BUY)- Recordati (REC IM: €53.15, BUY)- Redcare Pharmacy (RDC GR: €81.45, BUY)- Roche (ROG SW: CHF261.00, HOLD)- Sandoz Group AG (SDZ SW: CHF50.36, HOLD)- Sanofi (SAN FP: €85.36, BUY)- Siegfried Holding AG (SFZN SW: CHF84.30, HOLD)- Smith & Nephew (SN/ LN: p1,377.00, BUY)- Sonova (SOON SW: CHF231.10, HOLD)- Spire Healthcare Group PLC (SPI LN: p221.00, BUY)- SwedenCare AB (SECARE SS: SEK40.40, BUY)- Swedish Orphan Biovitrum AB (SOBI SS: SEK291.20, HOLD)- Vimian Group AB (VIMIAN SS: SEK31.56, HOLD)- Zealand Pharma A/S (ZEAL DC: DKK441.40, BUY)",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ea85a4f6aa598425",
      "text": "Distribution of Ratings",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ce3bd5c76007a432",
      "text": "CountPercentCountPercentCountPercentBUY211160.63%37017.53%1185.59%HOLD121334.84%1058.66%221.81%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "6b15308691ae75ac",
      "text": "Jffr  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  i  t  t  t  t  t  t  t  t  t  t  e  t  t  t",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "d966a4edd8d71856",
      "text": "financial situation, or needs.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "b2bf82f71ce0dbeb",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "61a20b4fe0472af8",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "e5e49eb4f1344076",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "bdb963b64caa6d3b",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "92f58e63c390fec8",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "9046ff55b9f0bf29",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "eba0bfc919bdf344",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 18,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "093bc15198b29903",
      "name": "ARDs of Pets at Home Group",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "85209ee882f03013",
      "name": "Abilify Maintena",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2a857fe3567685e4",
      "name": "Adam Steensberg",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cdf47ce481ecd695",
      "name": "Adela Dashian",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d4c401daa76add02",
      "name": "Alan Hippe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a53afd3643247764",
      "name": "Alexander Siedler",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "81b1ec9b915bb9ca",
      "name": "Alicia Cahill",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "34456f9635c3e320",
      "name": "Andrew Porteous",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2883d84d6ccb5aaf",
      "name": "Animal Health",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e755d6ac983146d5",
      "name": "Associate Director",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a99050f978a6bc4a",
      "name": "Bayer AG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8d67a09cdb447116",
      "name": "Belmonte Encina",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ae54718a7e080cb",
      "name": "Benjamin Jackson",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "098240bfadec2604",
      "name": "Big Box",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ad8c325078cdfa50",
      "name": "Biovitrum AB",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "64d11f9a391b72aa",
      "name": "Blueprint Medicines",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0035808db08cf525",
      "name": "Blueprint Medicines Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "80e683a44127748f",
      "name": "Boston Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "167513f20b8e4fe2",
      "name": "Britta Hamberger",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f6f7f84938de7dda",
      "name": "Bruno Eschli",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": "HEALTH CARE Fireside Chat Series",
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "6fc4e0325a5b5a42",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "other",
        "title": "HEALTH CARE Fireside Chat Series",
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "9c48257a04697ea9",
        "provenance": {
          "page": 1
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "acf3da7f61f5e064",
        "value": 300.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "elopment, which continues to be a top priority, with the aim of targeting assets with peak sales of €300- 800m, as well as its pipeline with the anticipated readout of long- acting neurotoxin for aest",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "26d3e39c3a19c74f",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "o/FX, activism and appealing valuation, SN has been perceived as a 'safe haven' with the shares up >10% YTD (one of the best perf in the sector). This will be a good opportunity to discuss with CEO ho",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "5e18b4a129dffd68",
        "value": 40.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "ireside chat will be exploring the pipeline opportunities that underpin confidence in management's >£40bn 2031 sales aim. In particular, we will discuss the set up for campilixant for chronic cough ah",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f09635a54b655d3e",
        "value": 0.6063000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "d76d7b348b11bca5",
        "value": 0.1753,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "5b238465ef4e2603",
        "value": 0.0559,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "88509cd297bbd418",
        "value": 0.34840000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158<",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "061ac0c406eef554",
        "value": 0.0866,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "1f4aa07ca7f5e0cf",
        "value": 0.0181,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "a529a88e964919c6",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "95499866073712fb",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "c74682fc340d877c",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "e069317cac61f955",
        "value": 11.4,
        "unit": "€",
        "metric_type": "currency",
        "context": "# Jefferies - Almirall (ALM SM: €11.40, BUY)- Bayer AG (BAYN GR: €27.93, HOLD)- CVS Group (CVSG LN: p1,270.00, HOLD)- Camurus AB (CAMX SS:",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "fe8ae3dc6b05994f",
        "value": 27.93,
        "unit": "€",
        "metric_type": "currency",
        "context": "# Jefferies - Almirall (ALM SM: €11.40, BUY)- Bayer AG (BAYN GR: €27.93, HOLD)- CVS Group (CVSG LN: p1,270.00, HOLD)- Camurus AB (CAMX SS: SEK726.50, BUY)- Cosmo (COPN SW:",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "5f0587071ab5a5ba",
        "value": 33.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "Cosmo (COPN SW: CHF62.40, BUY)- Demant (DEMANT DC: DKK243.00, HOLD)- Dermapharm Holding SE (DMP GR: €33.00, HOLD)- Diagnostyka (DIA PW: PLN203.80, BUY)- DocMorris AG (DOCM SW: CHF6.61, BUY)- Elekta (E",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "92d12361c93b79b2",
        "value": 43.1,
        "unit": "€",
        "metric_type": "currency",
        "context": "rris AG (DOCM SW: CHF6.61, BUY)- Elekta (EKTAB SS: SEK46.64, HOLD)- Fresenius Medical Care (FME GR: €43.10, UNDERPERFORM)- Fresenius SE (FRE GR: €46.36, BUY)- GSK Plc (GSK LN: p1,459.50, HOLD)- Galder",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "5f167ba4620d1d54",
        "value": 46.36,
        "unit": "€",
        "metric_type": "currency",
        "context": "B SS: SEK46.64, HOLD)- Fresenius Medical Care (FME GR: €43.10, UNDERPERFORM)- Fresenius SE (FRE GR: €46.36, BUY)- GSK Plc (GSK LN: p1,459.50, HOLD)- Galderma Group AG (GALD SW: CHF139.80, BUY)- Gedeon",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "acee99945d64decf",
        "value": 117.9,
        "unit": "€",
        "metric_type": "currency",
        "context": "/S (GMAB DC: DKK1,612.50, HOLD)- Hikma Pharmaceuticals plc (HIK LN: p1,815.00, BUY)- Ipsen (IPN FP: €117.90, HOLD)- Laboratorios Farmaceuticos Rovi SA (ROVI SM: €58.35, BUY)- Lundbeck (HLUNB DC: DKK40",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "fe11fd23fe1f2197",
        "value": 58.35,
        "unit": "€",
        "metric_type": "currency",
        "context": "IK LN: p1,815.00, BUY)- Ipsen (IPN FP: €117.90, HOLD)- Laboratorios Farmaceuticos Rovi SA (ROVI SM: €58.35, BUY)- Lundbeck (HLUNB DC: DKK40.38, HOLD)- Novartis AG (NOVN SW: CHF101.54, HOLD)- Orion Oyj",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "842bf683e3959750",
        "value": 68.5,
        "unit": "€",
        "metric_type": "currency",
        "context": "- Lundbeck (HLUNB DC: DKK40.38, HOLD)- Novartis AG (NOVN SW: CHF101.54, HOLD)- Orion Oyj (ORNBV FH: €68.50, BUY)- Oxford BioMedica plc (OXB LN: €5.71, BUY)- Pets at Home Group Plc (PETS LN: p227.80, B",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "0f306885b6b8cad6",
        "value": 5.71,
        "unit": "€",
        "metric_type": "currency",
        "context": "tis AG (NOVN SW: CHF101.54, HOLD)- Orion Oyj (ORNBV FH: €68.50, BUY)- Oxford BioMedica plc (OXB LN: €5.71, BUY)- Pets at Home Group Plc (PETS LN: p227.80, BUY)- Qiagen (QGEN: $46.14, BUY)- Recordati (",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "233b1efda727fe2d",
        "value": 46.14,
        "unit": "$",
        "metric_type": "currency",
        "context": "d BioMedica plc (OXB LN: €5.71, BUY)- Pets at Home Group Plc (PETS LN: p227.80, BUY)- Qiagen (QGEN: $46.14, BUY)- Recordati (REC IM: €53.15, BUY)- Redcare Pharmacy (RDC GR: €81.45, BUY)- Roche (ROG SW",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "315cd1854caf634b",
        "value": 53.15,
        "unit": "€",
        "metric_type": "currency",
        "context": "UY)- Pets at Home Group Plc (PETS LN: p227.80, BUY)- Qiagen (QGEN: $46.14, BUY)- Recordati (REC IM: €53.15, BUY)- Redcare Pharmacy (RDC GR: €81.45, BUY)- Roche (ROG SW: CHF261.00, HOLD)- Sandoz Group ",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "a4c68f0d7ed59977",
        "value": 81.45,
        "unit": "€",
        "metric_type": "currency",
        "context": "27.80, BUY)- Qiagen (QGEN: $46.14, BUY)- Recordati (REC IM: €53.15, BUY)- Redcare Pharmacy (RDC GR: €81.45, BUY)- Roche (ROG SW: CHF261.00, HOLD)- Sandoz Group AG (SDZ SW: CHF50.36, HOLD)- Sanofi (SAN",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "87f74e9e1dc97789",
        "value": 85.36,
        "unit": "€",
        "metric_type": "currency",
        "context": "5, BUY)- Roche (ROG SW: CHF261.00, HOLD)- Sandoz Group AG (SDZ SW: CHF50.36, HOLD)- Sanofi (SAN FP: €85.36, BUY)- Siegfried Holding AG (SFZN SW: CHF84.30, HOLD)- Smith & Nephew (SN/ LN: p1,377.00, BUY",
        "provenance": {
          "page": 15
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 2,
      "tables_count": 0,
      "numerical_data_count": 25,
      "passages_count": 178,
      "entities_count": 20
    }
  }
}